Talis Biomedical Corp
NASDAQ:TLIS
Income Statement
Earnings Waterfall
Talis Biomedical Corp
Income Statement
Talis Biomedical Corp
| Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||
| Revenue |
12
N/A
|
11
-10%
|
18
+60%
|
17
-4%
|
8
-55%
|
8
+8%
|
4
-47%
|
5
+10%
|
5
+12%
|
5
-11%
|
3
-41%
|
3
+0%
|
2
-23%
|
2
-3%
|
1
-54%
|
0
-59%
|
|
| Gross Profit | |||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
(4)
|
(5)
|
(6)
|
(8)
|
(5)
|
(4)
|
(2)
|
(0)
|
(0)
|
(0)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
(0)
N/A
|
(1)
-219%
|
(2)
-41%
|
(4)
-138%
|
(2)
+43%
|
(1)
+64%
|
(0)
+77%
|
2
N/A
|
1
-54%
|
0
-60%
|
|
| Operating Income | |||||||||||||||||
| Operating Expenses |
(66)
|
(102)
|
(162)
|
(215)
|
(215)
|
(200)
|
(165)
|
(127)
|
(115)
|
(112)
|
(99)
|
(90)
|
(78)
|
(66)
|
(55)
|
(47)
|
|
| Selling, General & Administrative |
(10)
|
(13)
|
(18)
|
(26)
|
(35)
|
(42)
|
(47)
|
(46)
|
(42)
|
(41)
|
(35)
|
(32)
|
(30)
|
(25)
|
(26)
|
(26)
|
|
| Research & Development |
(57)
|
(89)
|
(143)
|
(190)
|
(180)
|
(158)
|
(118)
|
(81)
|
(73)
|
(71)
|
(64)
|
(57)
|
(48)
|
(41)
|
(29)
|
(20)
|
|
| Operating Income |
(54)
N/A
|
(91)
-68%
|
(144)
-58%
|
(199)
-38%
|
(207)
-4%
|
(192)
+8%
|
(164)
+14%
|
(127)
+23%
|
(116)
+9%
|
(115)
+0%
|
(101)
+12%
|
(90)
+11%
|
(78)
+14%
|
(64)
+18%
|
(54)
+15%
|
(46)
+14%
|
|
| Pre-Tax Income | |||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(3)
|
(3)
|
(8)
|
(9)
|
|
| Total Other Income |
(0)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
1
|
2
|
3
|
4
|
5
|
5
|
5
|
4
|
|
| Pre-Tax Income |
(55)
N/A
|
(91)
-67%
|
(144)
-58%
|
(199)
-38%
|
(208)
-4%
|
(192)
+7%
|
(165)
+14%
|
(127)
+23%
|
(115)
+10%
|
(113)
+2%
|
(98)
+13%
|
(86)
+12%
|
(75)
+12%
|
(62)
+18%
|
(57)
+8%
|
(51)
+11%
|
|
| Net Income | |||||||||||||||||
| Income from Continuing Operations |
(55)
|
(91)
|
(144)
|
(199)
|
(208)
|
(192)
|
(165)
|
(127)
|
(115)
|
(113)
|
(98)
|
(86)
|
(75)
|
(62)
|
(57)
|
(51)
|
|
| Net Income (Common) |
(1)
N/A
|
(91)
-12 663%
|
(144)
-58%
|
(199)
-38%
|
(208)
-4%
|
(192)
+7%
|
(165)
+14%
|
(127)
+23%
|
(115)
+10%
|
(113)
+2%
|
(98)
+13%
|
(86)
+12%
|
(75)
+12%
|
(62)
+18%
|
(57)
+8%
|
(51)
+11%
|
|
| EPS (Diluted) |
-0.45
N/A
|
-58.22
-12 838%
|
-84.39
-45%
|
-116.18
-38%
|
-120.74
-4%
|
-127.17
-5%
|
-93.27
+27%
|
-71.63
+23%
|
-64.58
+10%
|
-63.65
+1%
|
-54.69
+14%
|
-47.22
+14%
|
-41.49
+12%
|
-34.12
+18%
|
-31.39
+8%
|
-28.02
+11%
|
|